

Claims:

1. Monoclonal murine internal image anti-idiotypic antibodies (Ab2) to monoclonal antibodies BR55-2 (Ab1).
2. Process for the production of anti-idiotypic antibodies according to claim 1 which comprises immunizing mice with BR55-2/murine IgG3-F (ab')₂-KLH-conjugate, fusing the murine spleen cells with the murine myeloma cell line SP 2/0, selecting the cultured hybridoma cells which produce IgG with an inhibition capacity of more than 95% (inhibition of binding of BR55-2 murine IgG2a to the SKBR5 cell line), purifying and isolating the anti-idiotypic antibody.
3. Use of anti-idiotypic antibodies according to claim 1 for prophylactic and/or therapeutic immunization against HIV-infections.
4. A method of immunization against HIV-infections which comprises administering to a subject in need of such treatment a therapeutically effective amount of an anti-idiotypic antibody according to claim 1.
5. A pharmaceutical composition which comprises as active agent an anti-idiotypic antibody according to claim 1 together with a pharmaceutically acceptable adjuvant, carrier or diluent for use in the prophylactic and/or therapeutic immunization against HIV-infections.
6. Use of monoclonal anti-idiotypic antibodies as defined in claim 1 for immunization against cancer of epithelial origin and against small cell lung cancer.
7. A pharmaceutical composition which comprises an anti-idiotypic monoclonal antibody as defined in claim 1 together with a pharmaceutically acceptable adjuvant, carrier or diluent for immunization against cancer of epithelial origin and against small cell lung cancer.
8. A method of immunization against cancer of epithelial origin and against small cell

lung cancer, which comprises administering to a subject in need of such a treatment an effective amount of an anti-idiotypic monoclonal antibody as defined in claim 1.

9. Use of anti-idiotypic antibodies according claim 1 for the quantitative determination of monoclonal antibodies, their derivatives or fragments with binding specificity of BR55-2.

10. Use of anti-idiotypic antibodies according claim 1 for the quantitative determination of monoclonal mouse/human chimeras of BR55-2 and of fully humanized variants of BR55-2.

11. Use of anti-idiotypic antibodies according claim 1 for a single step immuno-purification of variants of BR55-2.